Clinical Trials & ApprovalsThe initiation of the Phase 3 accelerated approval trial of IFx-2.0 in patients with advanced or metastatic Merkel cell carcinoma is a significant step forward for Tuhura Biosciences.
Financial PerformanceTuhura Biosciences announced it entered into an equity financing that should bring in an aggregate $12.5M in capital, providing financial runway into the first half of 2026.
Mergers & AcquisitionsThe merger with Kineta Inc has been approved by stockholders, promising to bring Kineta's anti-VISTA antibody into Tuhura's portfolio, potentially enhancing their research capabilities.